Position of the Polish Society for Inborn Errors of Metabolism on the diagnosis, treatment, and monitoring of patients with Gaucher disease

Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient glucocerebrosidase activity and accumulation of glucosylceramide within macrophages. Three main clinical forms are distinguished according to the presence and extent of central nervous system involvement: non-neuronopathic type 1 (GD1), acute neuronopathic type 2, and chronic neuronopathic type 3. The disease presents with a broad spectrum of manifestations, including hepatosplenomegaly, thrombocytopenia, skeletal complications, pulmonary involvement, and neurological symptoms in neuronopathic forms. This position statement of the Polish Society for Inborn Errors of Metabolism summarizes current recommendations for the diagnosis, treatment, and monitoring of patients with GD. The document discusses the molecular background, epidemiology, clinical presentation, diagnostic algorithms, biomarkers, imaging modalities, and severity assessment tools. Particular attention is given to enzyme replacement therapy, which remains the standard of care for GD1 and type 3 GD, and to substrate reduction therapy with eliglustat in selected adults with GD1. The role of supportive treatment, management during pregnancy, monitoring of therapeutic efficacy, multidisciplinary care, and transition from pediatric to adult services is also addressed. Emerging therapeutic approaches, including pharmacological chaperones and gene therapy, are reviewed. The recommendations emphasize early diagnosis, individualized treatment, and long-term follow-up in specialized reference centers.

Authors

Publication Details

Journal
Polskie Archiwum Medycyny Wewnętrznej
Published
2026-11-16
DOI
https://doi.org/10.20452/pamw.17445
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Position of the Polish Society for Inborn Errors of Metabolism on the diagnosis, treatment, and monitoring of patients with Gaucher disease

Marek A. Ruchała, Agnieszka Gala‐Błądzińska, Beata Kieć‐Wilk, Robert Stanisław Śmigiel et al.
Polskie Archiwum Medycyny Wewnętrznej
Lysosomal Storage Disorders Research
article

Position of the Polish Society for Inborn Errors of Metabolism on the diagnosis, treatment, and monitoring of patients with Gaucher disease

Marek A. Ruchała, Agnieszka Gala‐Błądzińska, Beata Kieć‐Wilk, Robert Stanisław Śmigiel, Grzegorz Witkowski, Anna Szmigielska‐Kapłon, Jolanta Sykut‐Cegielska, Wierzba Jolanta, Krzysztof Kuziemski, Tomasz Ociepa
article en

Abstract

Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient glucocerebrosidase activity and accumulation of glucosylceramide within macrophages. Three main clinical forms are distinguished according to the presence and extent of central nervous system involvement: non-neuronopathic type 1 (GD1), acute neuronopathic type 2, and chronic neuronopathic type 3. The disease presents with a broad spectrum of manifestations, including hepatosplenomegaly, thrombocytopenia, skeletal complications, pulmonary involvement, and neurological symptoms in neuronopathic forms. This position statement of the Polish Society for Inborn Errors of Metabolism summarizes current recommendations for the diagnosis, treatment, and monitoring of patients with GD. The document discusses the molecular background, epidemiology, clinical presentation, diagnostic algorithms, biomarkers, imaging modalities, and severity assessment tools. Particular attention is given to enzyme replacement therapy, which remains the standard of care for GD1 and type 3 GD, and to substrate reduction therapy with eliglustat in selected adults with GD1. The role of supportive treatment, management during pregnancy, monitoring of therapeutic efficacy, multidisciplinary care, and transition from pediatric to adult services is also addressed. Emerging therapeutic approaches, including pharmacological chaperones and gene therapy, are reviewed. The recommendations emphasize early diagnosis, individualized treatment, and long-term follow-up in specialized reference centers.

Polskie Archiwum Medycyny Wewnętrznej
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon